YAbS







Crexavibart, ogalvibart Terminated Mixture of 2

Antibody Information

Entry ID 1967
INN Crexavibart, ogalvibart
Status Terminated
Drug code(s) C144-LS, C-135-LS, BMS-986413, BMS-986414
Brand name None
mAb sequence source mAb - source TBD
General Molecular Category Mixture of 2
Format, general category Full length Ab
Format details None
Isotype (Fc) IgG1
Light chain isotype kappa
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) SARS-CoV-2 (spike protein)
Indications of clinical studies COVID-19
Primary therapeutic area Infectious diseases

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Terminated at Phase 2/3
Status Inactive
Start of clinical phase (IND filing or first Phase 1) January 11, 2021
Start of Phase 2
Start of Phase 3
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Bristol Myers Squibb
Licensee/Partner Rockefeller University
Comments about company or candidate Not mentioned in BMS Q2 2022 results presentation dated July 27, 2022.
Included in NIH's NCT04518410 Phase 2/3 study
Feb 2021: Bristol Myers Squibb has secured global rights to a pair of anti-SARS-CoV-2 antibodies discovered by The Rockefeller University.
NCT04700163 Phase 1 study started in Jan 2021.
Full address of company New York, United States
North America
United States of America
https://www.bms.com/in

Description/comment

A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein. LS mutation (M428L/N434S) extends half-life (https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009688)

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None